Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711868 | 0.90 | MAPK8 (0.49) | ENPP2PPARGMRGPRX4 | |
| SCHEMBL15998618 | 0.88 | ENPP2 (0.46) | ENPP2PPARGMRGPRX4 | |
| SCHEMBL4568156 | 0.87 | PPARG (0.45) | ENPP2PPARG | |
| SCHEMBL4568144 | 0.85 | PPARG (0.51) | ENPP2PPARGMRGPRX4 | |
| SCHEMBL4568160 | 0.84 | MRGPRX4 (0.44) | ENPP2PPARGMRGPRX4PTGER1 | |
| SCHEMBL4568150 | 0.83 | ENPP2 (0.57) | ENPP2PPARGPLA2G4ACCR2MRGPRX4 | |
| SCHEMBL4568162 | 0.82 | MRGPRX4 (0.49) | PPARGMRGPRX4 | |
| SCHEMBL4568154 | 0.80 | PPARG (0.42) | PPARGTACR1MRGPRX4 | |
| SCHEMBL4568149 | 0.79 | ENPP2 (0.59) | ENPP2PTGER1 | |
| SCHEMBL4568129 | 0.78 | HPGD (0.45) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | ENPP2 595/4885PPARG 500/4885PLA2G4A 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.